Neutrophil Granules and Their Proteases {#Sec1}
=======================================

Neutrophil Biology and Neutrophil Serine Proteases {#Sec2}
--------------------------------------------------

Neutrophils are white blood cells with a prominent function in the control of microbes at mucosal surfaces and in tissues. The containment and elimination of bacteria and fungi can be severely affected if too few neutrophils are available or if there is a defect in their ability to reach the infection site. Neutrophils carry a vast repertoire of antimicrobial molecules and enzymes that directly contribute to killing pathogens. While neutrophils are essential to fight bacterial and fungal infections, the presence and death of neutrophils at inflammatory sites has been associated with delayed healing, tissue damage, and pathogenesis of chronic diseases. For these reasons, neutrophils and their potentially harmful granule cargo have been considered a double-edged sword in inflammatory diseases. Neutrophils are now emerging as a central orchestrator of inflammatory responses and their resolution through continuous interactions with components of the innate and adaptive responses (Nathan [@CR55]; Kruger et al. [@CR46]). In this chapter, the function of the neutrophil granule serine proteases in neutrophil life cycle and their function in host defense and in inflammatory diseases will be reviewed with a special focus on their regulation by intracellular serpins.

Neutrophils develop in the bone marrow from hematopoietic stem cells and differentiate progressively through progenitors with more restricted lineage potential known as the common myeloid progenitors and the granulocyte-macrophage progenitors (GMPs). The transcription factor PU.1 is essential for the generation of GMPs. At the GMP stage, the expression of the transcription factors, CCAAT/enhancer-binding protein-α (C/EBPα) and growth factor independent-1 (GFI-1), appears essential for commitment toward the neutrophil lineage, whereas PU.1 promotes monocyte differentiation (Cheng et al. [@CR20]; Zhang et al. [@CR79]; Dahl et al. [@CR25]). C/EBP-α and GFI-1 promote proliferation of neutrophil precursors from myeloblasts, promyelocytes, and myelocytes, known as the mitotic pool of neutrophils in the bone marrow. These transcription factors are also key for the expression of neutrophil serine proteases and other primary granule proteins such as myeloperoxidase and defensins at the promyelocyte stage. As C/EPB-α and GFI-1 levels diminish, terminal granulocytic differentiation to mature neutrophils is under the transcriptional regulation of C/EBP-ε, which controls the expression of secondary and tertiary granule proteins. These stages are also known as the postmitotic pool of neutrophils. Mature neutrophils accumulate in the bone marrow as a large reserve pool that can be rapidly released to the circulation. During the last phase of differentiation, neutrophils start expressing receptors to transduce signals for mobilization to the blood and for effector functions. Once in the blood circulation, neutrophils have a relatively short life span of a few hours. They can sense tissue injury through cytokines, peptides, and lipid mediators secreted and/or presented by endothelial cells. Once firmly arrested on the vascular endothelium, neutrophils migrate into the tissue in a highly directional manner toward the injury site. Recruited neutrophils are highly efficient phagocytes and kill microbes using a broad range of antimicrobial peptides and enzymes. In the absence of inflammation, the neutrophil life cycle ends by efferocytosis, where neutrophils undergo apoptosis and are phagocytosed. Efferocytosis of neutrophils occurs in all tissues but, in steady-state conditions, it occurs principally in the spleen, the liver, and the bone marrow. This form of cell death is important for several reasons (Vandivier et al. [@CR74]). First, it dampens the production of inflammatory mediators through the production of TGF-β, for example. Second, and in contrast to necrotic neutrophils, apoptotic neutrophils do not release their highly reactive contents, thus preventing damage to neighboring cells and extracellular matrix proteins. Third, impaired removal of apoptotic cells is associated with autoimmune disease. Last but not least, phagocytosis of apoptotic neutrophils reduces the production of IL-23 by the macrophages. IL-23 induces the production of IL-17 by αβ and γδ T cells. IL-17, in turn, upregulates G-CSF production by stromal cells leading to increased granulopoiesis (Stark et al. [@CR71]). Therefore, the removal of apoptotic cells in the periphery sends a negative feedback loop that ultimately regulates neutrophil production in the bone marrow.

Granule Subsets and Protease Packaging {#Sec3}
--------------------------------------

Neutrophil serine proteases (NSPs) contribute to many aspects of neutrophil biology in host defense and diseases associated with neutrophilic inflammation (Pham [@CR58]). Human neutrophils contain four NSPs with an active catalytic triad: neutrophil elastase (NE), proteinase-3 (PR3), cathepsin G (CG), and the recently characterized neutrophil serine protease-4 (NSP4). NE and PR3 are elastinolytic proteases, and CG has chymotrypsin-like activity, whereas NSP4 is a trypsin-like protease. Azurocidin is encoded by a phylogenetically related serine protease gene, but its catalytic domain is mutated rendering the protease inactive. NSPs evolved from a common ancestor and are phylogenetically related to other serine proteases found in innate immune cells including granzymes and mast cell proteases (Ahmad et al. [@CR2]). NSPs are conserved in mice, and in contrast to granzymes and mast cell proteases, there is a single mouse homolog for each of the human NSP genes.

Neutrophils contain three types of granules (primary, secondary, and tertiary) and secretory vesicles. NSPs are principally stored in primary, also termed azurophil, granules. However, PR3 was also reported in other types of granules and secretory vesicles. Together with NSPs, primary granules carry myeloperoxidase, lysozyme, and antimicrobial peptides such as α-defensins and cathelicidin. How each cargo protein ends up in the correct granule appears largely controlled by transcriptional timing (Cowland and Borregaard [@CR23]; Theilgaard-Mönch et al. [@CR73]). As described above, different transcription factors dominate at different phases of neutrophil differentiation and mRNA expression of NSPs is highest in promyelocytes, which is the time where primary granules are formed.

NSPs are synthesized as pre-pro-enzymes and require posttranslational cleavage at the N-terminus and C-terminus to gain their fully mature active form. First, the signal peptide is cleaved by a signal peptidase. The resulting pro-enzymes are then further processed by dipeptidyl peptidase I (DPPI), also known as cathepsin C, which cleaves the N-terminal dipeptide in the endoplasmic reticulum (ER) and Golgi apparatus before packaging into granules. Cleavage of the pro-dipeptide by DPPI is essential for the enzymatic activity of the NSPs. Neutrophils of *dppi* ^*−/−*^ mice have no detectable NSP activity, and CG protein is not detectable in neutrophil lysates (Adkison et al. [@CR1]). The C-terminus of the pro-enzymes is also cleaved before packaging into granules, but the protease responsible for this process has not yet been identified. Mutants of NE and CG lacking the C-terminal peptide and expressed in RBL cell line are correctly routed to granules and are enzymatically active indicating that the C-terminal domain is not required for these functions (Gullberg et al. [@CR36]).

The mechanisms of targeting and retention of NSPs in primary granules are not fully elucidated. Cleavage of the C-terminus of NE appears to promote the routing of NE to granules by two mechanisms: first, the C-terminus contains a putative transmembrane domain that leads to membrane anchoring and leads to targeting to the plasma membrane; second, the cleavage of the C-terminus leads to the uncovering of a binding domain for adaptor protein complex 3 (AP3), which may favor protein distribution to granules (Benson et al. [@CR13]). The proteoglycan serglycin contributes to the retention of proteases and inflammatory mediators in leukocytes and endothelial cells (Kolset and Tveit [@CR45]). In neutrophils of serglycin-deficient mice, only NE appeared to require serglycin for proper localization into granules, whereas sorting of CG and PR3 was not affected (Niemann et al. [@CR56]). While early studies showed that PR3 localized principally in primary granules (Borregaard and Cowland [@CR16]), PR3 has also been reported in secretory vesicles and other types of granules, which may explain the more rapid mobilization of PR3 to the plasma membrane (Witko-Sarsat et al. [@CR77]; Loison et al. [@CR49]).

NSP Inhibitors {#Sec4}
==============

Secreted Clade A Serpins {#Sec5}
------------------------

Several inhibitors of the clade A and the clade B serpins, as well as non-serpin inhibitors of the macroglobulin and chelonianin families, contribute to the regulation of the activity of NSPs in different compartments of the cell, tissues, and the whole organism.

The clade A serpins α1- antitrypsin ( AAT, SERPINA1) and α1-antichymotrypsin (ACT, SERPINA3) are the two principal serpins found in plasma that inhibit NSPs. AAT inhibits NE, CG, and PR3 by the classical suicide-substrate mechanism of serpins (Huntington et al. [@CR38]). The three NSPs cleave the reactive center loop (RCL) of AAT at the same P1 site Met-358. ACT, in contrast, inhibits only CG. AAT and ACT are produced by the liver and respiratory airway epithelial cells and function by regulating NSPs in blood and extracellular compartments when NSPs are released from neutrophils following degranulation or necrosis.

AAT is also expressed in neutrophils during the late stages of granulopoiesis in the bone marrow and is found at relatively higher levels in mature differentiated cells (Missen et al. [@CR53]). AAT protein is found within neutrophil granules and can be secreted upon stimulation (Mason et al. [@CR52]; Clemmensen et al. [@CR21]). In circulating neutrophils, AAT levels in neutrophils are increased as the secretory vesicles are formed by engulfing plasma proteins that can later be released in response to inflammatory stimuli (Borregaard et al. [@CR17]). The relative importance and function of AAT within the different granules of neutrophils in homeostatic and inflammatory conditions remain to be defined. There is also growing evidence that AAT functions as an anti-inflammatory mediator independently of NSP inhibition (Jonigk et al. [@CR39]). One mechanism may be through interference with TNF-α signaling pathways (Bergin et al. [@CR14]).

In mice and rats, AAT and ACT genes have been duplicated multiple times. The number of AAT genes and plasma concentrations appear to vary between different laboratory mouse strains. Modeling AAT deficiency by deleting the mouse genes has proved to be even more challenging because of embryonic lethality (Wang et al. [@CR75]).

Intracellular Clade B Serpins {#Sec6}
-----------------------------

Clade B serpins regroup phylogenetically related proteins with nuclear and/or cytoplasmic localization. Vertebrate clade B serpins evolved from a single serpinB1-like gene that has remained conserved in fish, birds, and mammals (Kaiserman and Bird [@CR40]; Benarafa and Remold-O'Donnell [@CR9]). In man, there are 13 clade B serpins found on two loci. *SERPINB1*, *SERPINB6,* and *SERPINB9* genes are found on chromosome 6p25, and the ten other clade B serpin genes are clustered on chromosome 18q21. Serpins encoded in the 6p25 cluster inhibit granule serine proteases of leukocytes, and high expression of these serpins is found in cells that also carry target proteases.

SERPINB1 was the first cytoplasmic inhibitor of elastase to be identified in neutrophils and monocytes/macrophages (Remold-O'Donnell [@CR62], [@CR63]; Potempa et al. [@CR61]). It was thus named monocyte/ neutrophil elastase inhibitor (MNEI) and leukocyte elastase inhibitor (LEI). SERPINB1 also inhibits CG and PR3 through the classical serpin complex inhibition mechanism. NE and PR3 target the RCL of SERPINB1 at Cys-344 at the classical P1 position, corresponding to Met-358 of AAT. In contrast, CG and other chymotrypsin-like proteases cleave the reactive center loop (RCL) of SERPINB1 at Phe-343 (Cooley et al. [@CR22]). SERPINB1 is expressed in most tissues with higher levels in lymphoid organs such as the bone marrow and the spleen as well as in the pancreas and the lungs. In hematopoietic cells, SERPINB1 is expressed in stem cells, all leukocyte lineages, and platelets. SERPINB1 levels are the highest in the neutrophil lineage, where highest mRNA expression is found in the early stages of granulopoiesis and protein levels remain high in bone marrow and blood neutrophils (Benarafa et al. [@CR10]; Missen et al. [@CR53]). Its role in neutrophil homeostasis is further described below.

SERPINB6, previously described as proteinase inhibitor-6 (PI-6), inhibits CG but not NE and PR3 (Scott et al. [@CR69]). SERPINB6 is also broadly expressed in various tissues and cells with high levels in all myeloid cells with relatively higher levels in monocytic/dendritic cells (Scarff et al. [@CR66]; Missen et al. [@CR53]).

First identified as squamous cell carcinoma antigen (SCCA), SERPINB4 (SCCA2) is also an inhibitor of CG but with slower association rate constants than SERPINB6 and SERPINB1 (Schick et al. [@CR68]). Its closest homolog in mice, *serpinb3a*, also inhibits CG but is not expressed in hematopoietic cells (Al-Khunaizi et al. [@CR4]; Askew et al. [@CR5]).

Non-serpin Inhibitors of NSPs {#Sec7}
-----------------------------

α2-Macroglobulin (α2M) is a very large (725 kDa) protease inhibitor found in plasma. It inhibits NSPs as well as many other serine proteases by a cleavage-induced conformational change that traps the proteases into a cavity within α2M (Barrett and Starkey [@CR6]). In contrast to serpin-protease complexes, proteases trapped by α2M can still cleave small molecular weight substrates that can reach the proteolytic domain of the protease. Because of its large size, the diffusion of α2M into tissues during inflammation was considered to be limited and its realm of activity is thus likely limited to the blood circulation, where it regulates fibrinolysis, coagulation, complement, and NSPs (de Boer et al. [@CR28]). However, α2M is found in the lung epithelial lining fluid in adult respiratory distress syndrome (ARDS), where it traps elastase and prevents cleavage of large substrates (Wewers et al. [@CR76]).

Secretory leukocyte protease inhibitor (SLPI) and elafin are two chelonianins that are secreted by epithelial cells and contribute to inhibition of extracellular NSPs at mucosal surfaces and in tissues (Sallenave [@CR65]). They use a reversible keyhole type of inhibition, where the small approximately 10 kDa inhibitors bind the catalytic pocket of the protease with high affinity. SLPI inhibits both NE and CG, while elafin inhibits NE and PR3.

The relative importance of each inhibitor depends on expression levels, compartmentalization, and posttranslational modifications. In addition, because NSPs are usually released together, inhibitors that are inactivated by proteolysis by one NSP may be disarmed before inhibiting their target. While redundancy and compensatory mechanisms are expected and observed between the different inhibitors, essential physiological functions have also been attributed to individual NSP inhibitors.

Neutrophil Death in Steady-State Conditions {#Sec8}
===========================================

SERPINB1 has emerged as an important regulator of neutrophil survival. A cytoprotective function for intracellular serpins was postulated based on the presence of these inhibitors in cells carrying cell death-inducing granule proteases, such as granzymes (Bird [@CR15]). In the case of SERPINB1, expression profiling during granulopoiesis supported this hypothesis since mRNA and protein levels of SERPINB1 peaked in promyelocyte and myelocyte stages, which coincided with the high but transient transcription of NSPs and other primary granule proteins (Theilgaard-Mönch et al. [@CR73]; Benarafa et al. [@CR12]). The evidence that SERPINB1 is cytoprotective for neutrophil has been elucidated in a series of studies of mice with a targeted deletion of *serpinb1a* (Benarafa et al. [@CR11]), the mouse ortholog of the human gene (Benarafa et al. [@CR10]). In these mice, neutrophil numbers in the bone marrow are approximately 50 % of the levels of wild-type mice. The phenotype is highly penetrant as it is observed in 129S6 and C57BL/6J backgrounds. Circulating blood neutrophil numbers in *serpinb1a* ^−/−^ mice are only marginally lower than in wild-type mice in normal conditions, but a faster decline in circulating neutrophils is observed after myeloablation with cyclophosphamide (Benarafa et al. [@CR12]). In mice, reduction of neutrophil numbers in the bone marrow is physiologically relevant as it holds over 90 % of mature neutrophils. Indeed, laboratory strains of mice have on average 1 × 10^6^ neutrophils/ml of blood with a total volume of 2 ml; and a mouse femur represents approximately 6 % of the total bone marrow and contains 4--6 × 10^6^ neutrophils depending on the mouse strain.

Neutropenia in *serpinb1a* ^−/−^ mice is due to a cell intrinsic survival defect affecting differentiated neutrophils, while the development of mitotic neutrophil precursors is normal (Benarafa et al. [@CR12]). The mechanism of cell death in the absence of *serpinb1a* is dependent on CG in steady state in vivo. Indeed, neutropenia in *serpinb1a* ^−/−^ mice was fully rescued by deficiency in CG (*Ctsg* ^−/−^). In contrast, NE deficiency had no effect on neutrophil survival in *serpinb1a* ^−/−^ mice (Baumann et al. [@CR7]). Competitive stem cell transplantation of irradiated mice showed a survival advantage of wild-type neutrophils over *serpinb1a* ^−/−^ neutrophils but not over *Ctsg* ^−/−^.*serpinb1a* ^−/−^ double-deficient neutrophils. These mixed bone marrow chimera experiments demonstrated that neutrophil death was cell intrinsic in vivo and support intracellular leakage of granule proteins in mature neutrophils as a mechanism of cell death in the absence of SERPINB1. Importantly, mice lacking one or all three NSPs, as in *dppi* ^−/−^ mice, do not present increased neutrophil numbers in bone marrow and blood. These findings indicate that in homeostatic conditions, neutrophil homeostasis is not critically regulated by NSPs unless the intracellular anti-protease shield is deficient.

SERPINB6 may also contribute to neutrophil homeostasis in steady state as it is expressed in the cytoplasm of neutrophils and inhibits CG. However, mice deficient in *serpinb6a*, the ortholog of the human gene (Kaiserman et al. [@CR41]), do not present an obvious defect in neutrophil numbers in vivo (Scarff et al. [@CR67]). This somewhat surprising result may be explained by a compensatory increase in serpinb1a expression in bone marrow cells of *serpinb6a* ^−/−^ mice. The characterization of mice deficient in the two serpins may reveal complementary functions.

Spontaneous Neutrophil Death In Vitro {#Sec9}
=====================================

Mechanisms regulating neutrophil cell death are often investigated in vitro, where isolated neutrophils rapidly die by caspase-dependent apoptosis. This process is often referred to as spontaneous apoptosis. The survival of isolated neutrophils can be extended by addition of synthetic caspase inhibitors or by acting on upstream survival pathways. *Serpinb1a* ^−/−^ neutrophils also demonstrate reduced survival in vitro that is only partly inhibited by caspase inhibitors. In contrast, the survival defect is fully rescued if neutrophils are concomitantly deficient in CG, indicating that in the absence of serpinb1, CG induce neutrophil death through both caspase-dependent and caspase-independent pathways. While CG has been shown to activate caspase-7 (Zhou and Salvesen [@CR80]), the targets of CG leading to caspase-independent cell death are not yet know.

Interestingly, isolated neutrophils of mice deficient in PR3 (*prtn3* ^−/−^) show improved survival in vitro compared to WT neutrophils and PR3 is found in the cytoplasm of aging neutrophils in vitro. Inhibitory complexes between PR3 and serpinb1 are found in the cytoplasm of aging neutrophils, supporting the notion that granule leakage promotes cell death. In contrast to CG or NE, PR3 directly activates pro-caspase-3 leading to apoptosis (Loison et al. [@CR49]). Therefore, serpinb1 appears to act at the intersection of death pathways mediated by CG and PR3. It is conceivable that the two proteases function in a cascade because CG deletion alone rescues the cell intrinsic death pathway in *serpinb1a* ^−/−^ mice in vitro and in steady-state conditions in vivo. This hypothesis could be tested in *prtn3* ^−/−^.*serpinb1a* ^−/−^ double knockout mice. Alternatively, CG and PR3 could induce neutrophil death through parallel pathways that would enhance each other by depletion of the serpin shield.

Neutrophil Elastase and Severe Congenital Neutropenia {#Sec10}
=====================================================

Genetic Causes of Severe Congenital Neutropenia {#Sec11}
-----------------------------------------------

Severe congenital neutropenia (SCN) is a rare inherited disease characterized by persistently low neutrophil counts (\<500/μl) in blood and a maturation arrest of neutrophil precursors in the bone marrow. Infants with SCN consequently develop mouth ulcers and pneumonia that can be fatal. Mutations in the neutrophil elastase gene (*ELANE* or *ELA2*) are the cause of most cases of SCN and of all cases of cyclic neutropenia (CyN) (Dale et al. [@CR27]; Dale and Link [@CR26]). CyN is a milder form of SCN where blood neutrophil counts oscillate between normal and very low counts with a cyclic period of 21 days (Horwitz et al. [@CR37]).

SCN was first described in the 1950s by Dr. Rolf Kostmann in a family in northern Sweden. The genetic cause of the original cases of Kostmann's syndrome has recently been attributed to a homozygous mutation in the *HAX1* (HCLS1-associated protein X-1) gene (Klein et al. [@CR43]). Other infrequent causes of SCN include mutations in adenylate kinase 2 (*AK2*), the transcriptional repressor (*GFI1*), and the glucose-6-phosphatase *G6PC3* genes (Klein [@CR42]). X-linked neutropenia has also been described in a subset of patients with Wiskott-Aldrich syndrome (WAS) carrying activating mutations in the *WAS* gene (Albert et al. [@CR3]). Finally, a significant proportion of SCN cases remain genetically undefined, and with the advances in sequencing technology, new genetic defects leading to SCN will certainly be discovered (Boztug and Klein [@CR18]). Because it is genetically heterogeneous, several molecular pathways are likely leading to SCN.

ELANE Mutations in SCN and CyN {#Sec12}
------------------------------

Close to two hundred distinct mutations in *ELANE* have been identified in patients with SCN and CyN (Germeshausen et al. [@CR31]; Makaryan et al. [@CR51]). How mutant elastase leads to neutropenia is not completely elucidated, but the current working paradigm is that the mutated NE protein induces apoptosis in developing neutrophils in the bone marrow via the initiation of the unfolded protein response (UPR) (Köllner et al. [@CR44]; Grenda et al. [@CR35]). NE mutants are predicted to have defective folding as the protein is synthesized in the ER. Misfolded proteins are detected by ER sensors, which trigger the UPR that can ultimately lead to apoptosis. As very large amounts of mutant misfolded NE are produced at the promyelocyte stage, the UPR triggers apoptosis resulting in the absence of differentiated neutrophils in the bone marrow and blood. Genotype-phenotype analysis studies suggest that the pattern of mutations in *ELANE* is different in patients that develop SCN or CyN (Makaryan et al. [@CR51]). However, some mutations can lead to both SCN and CyN suggesting that additional disease modifiers may affect the severity of the phenotype (Germeshausen et al. [@CR31]). Furthermore, about 25 % of mutations leading to SCN, but none to CyN, are associated with the development of myelodysplasia (MDS) and acute myeloid leukemia (AML). However, only a fraction of the patients with these mutations also develop MDS/AML, indicating again that other genetic, epigenetic, and environmental factors contribute to disease initiation and progression.

A Role for Serpins in SCN? {#Sec13}
--------------------------

Whether mutations in intracellular serpin genes contribute to the severity of SCN or to the subsequent development of MDS/AML has yet to be demonstrated in humans. Studies presented above suggest that CG and PR3 can contribute to neutrophil death if the serpin shield is deficient as in *serpinb1a* ^−/−^ mice. In addition, *serpinb1a* ^−/−^ mice are more susceptible and succumb to lung infections with *Pseudomonas aeruginosa* (Benarafa et al. [@CR11]). However, the level of neutropenia observed in *serpinb1a* ^−/−^ mice is milder than that observed in SCN and no maturation arrest is observed in the bone marrow (Benarafa et al. [@CR12]).

Several studies have investigated NE activity in the context of *ELANE* mutations, and the combined evidence does not support a role for altered NE activity as the direct cause of neutrophil precursor death in the bone marrow. In transfection studies, recombinant NE mutants showed variable activity on peptide substrates ranging from the absence of activity, reduction in activity, to a higher activity than wild-type NE. In addition, AAT inhibited all active mutants in vitro (Li and Horwitz [@CR48]). Because SCN patients have heterozygous mutations in *ELANE*, it was hypothesized that mutant NE might interfere with wild-type NE. The overall NE activity was tested in blood neutrophils of SCN patients with or without *ELANE* mutations. In single cell assays by flow cytometry, which are associated with technical caveats such as dye loading standardization, average NE activity was similar in neutrophils of SCN patients and those of normal subjects, but the variation between individuals was greater in the SCN patient group (Germeshausen et al. [@CR31]). In the same study, NE activity in lysates of blood neutrophils of a small subset of SCN patients with mutated NE was significantly lower than the activity of neutrophil lysates of SCN patients without *ELANE* mutation and than that of normal donors. Therefore, *ELANE* mutations do not appear to be linked with consistently lower or higher NE activity. In addition, *elane* ^−/−^ mice have normal granulopoiesis and neutrophil counts (Belaaouaj et al. [@CR8]), further indicating that reduced or absent NE activity is not required for neutrophil survival and differentiation. Measurements of CG and PR3 activity and levels of SERPINB1 and SERPINB6 in neutrophils of SCN patients with or without *ELANE* mutations have not been investigated and may provide additional mechanistic clues on pathways leading to neutropenia.

Therapy and Mouse Models for SCN {#Sec14}
--------------------------------

G-CSF therapy is the standard treatment for almost all types of neutropenia, whether congenital or induced by chemotherapy. Long-term G-CSF therapy has considerably improved the quality of life and reduced mortality from infections in SCN patients (Rosenberg et al. [@CR64]). Yet, as in other severe inherited diseases with defects in hematopoiesis, there is a high long-term risk of developing malignancy. Therefore, better understanding of disease mechanisms may help design better targeted therapies for SCN. In *serpinb1a* ^−/−^ mice, G-CSF treatment increased precursor proliferation and accumulation of mature neutrophils in the bone marrow to levels comparable to those of untreated wild-type mice. However, G-CSF treatment failed to accumulate neutrophils in blood of *serpinb1a* ^−/−^ mice indicating that G-CSF therapy does not fully block NSP-mediated death in circulating cells (Baumann et al. [@CR7]).

Attempts at modeling SCN in mice expressing *ELANE* mutants found in SCN patients unfortunately did not live up to expectations. Knock-in mice expressing the human V72M mutant of NE instead of mouse NE did not develop SCN and had normal granulopoiesis in steady-state and in stress conditions (Grenda et al. [@CR34]). Another knock-in mouse expressing the G193X mutation that leads to the truncation of the carboxy-terminal 27 amino acids of the mature NE protein was also generated but similarly showed normal granulopoiesis in steady-state conditions (Nanua et al. [@CR54]). However, neutrophil precursors of mice carrying the G193X mutation showed reduced proliferation and survival after tunicamycin and bortezomib treatment, which block N-linked glycosylation and proteasome activity, respectively. These effects were associated with endoplasmic reticulum stress and markers of unfolded protein responses suggesting that modulating the unfolded protein response may be of therapeutic benefit. Finally, the overall lack of effect of these mutants may be due to the significantly lower expression levels of NE in mice compared to human neutrophils (Nanua et al. [@CR54]). Expressing *ELANE* mutants under the control of a stronger promoter may provide a model.

NSPs and Intracellular Serpins Beyond Neutrophils {#Sec15}
=================================================

Inflammatory Lung Disease {#Sec16}
-------------------------

AAT, SLPI, and elafin have been long established as part of the antiprotease shield against NSPs in the lungs (Greene and McElvaney [@CR33]). Most prominently, patients with AAT deficiency develop lung emphysema at a young age (Laurell and Eriksson [@CR47]). This finding is one of the pillars of protease-antiprotease paradigm of chronic lung disease, where NSPs destroy the lung elastin fibers and other matrix proteins leading to emphysema. Single nucleotide polymorphism that alters the protein sequence of ACT has also been associated with chronic obstructive pulmonary disease (Lomas and Silverman [@CR50]), suggesting that CG may contribute to pathogenesis.

SERPINB1 is also found in airway fluids during lung inflammatory disease (Cooley et al. [@CR81]; Davies et al. [@CR82]; Yasumatsu et al. [@CR84]). Indeed, SERPINB1 can be secreted by an alternative mechanism used by other leaderless cytoplasmic proteins such as IL-1 family members (Keller et al. [@CR83]). However, the relative importance of this secreting pathway and the release of SERPINB1 in the extracellular milieu after cell death remain to be established. Because AAT and SERPINB1 are both fast inhibitors of all three NSPs, a role for SERPINB1 in preventing the development and the severity of pulmonary emphysema in aging mice and following cigarette smoke exposure was tested in *serpinb1a* ^−/−^ mice. Serpinb1a was expressed in the lungs of control mice and expression was higher after cigarette smoke exposure. However, stereological analysis of the lungs and lung function tests revealed that *serpinb1a* ^−/−^ mice did not develop early onset emphysema as they aged. In addition, they developed cigarette smoke-induced emphysema to a comparable extent as wild-type mice after 6-month exposure (Cremona et al. [@CR24]). These findings suggest distinct functions for the intracellular and extracellular serpins in emphysema development.

Lung Infection Models {#Sec17}
---------------------

Excessive inflammatory host response increases morbidity and mortality associated with seasonal respiratory influenza, and highly pathogenic virus strains are characterized by massive infiltration of leukocytes that produce a storm of injurious cytokines. Following up on studies showing increased production of inflammatory cytokines in *P. aeruginosa* infection of *serpinb1a* ^−/−^ mice (Benarafa et al. [@CR11]), a role for SERPINB1 in influenza A virus infection was investigated. After challenge with a high-dose influenza A/Philadelphia/82 (H3N2), the survival of *serpinb1a* ^−/−^ mice was significantly reduced. Sublethally infected animals suffered increased morbidity, delayed resolution of lung injury, and increased immune cell death (Gong et al. [@CR32]). Importantly, early virus-induced cytokine and chemokine burst and influx of PMNs and monocytes were also normal, and these responses were associated with normal viral clearance in *serpinb1a* ^−/−^ mice compared to wild-type. Whereas initial cytokines and chemokines rapidly decreased in WT mice, TNF-α, IL-6, KC/CXCL1, G-CSF, IL-17A, and MCP-1/CCL2 remained elevated in *serpinb1a* ^−/−^ mice. Monocyte-derived cells were the dominant immune cells in influenza-infected lungs, and those from *serpinb1a* ^−/−^ mice produced more IL-6 and TNF-α when tested ex vivo (Gong et al. [@CR32]). Because viral clearance was unimpaired, the study highlights the critical role of serpinB1 in mitigating tissue injury, restricting inflammatory cytokine production, and reducing morbidity.

In lung infection models, *serpinb1a* ^−/−^ deficiency is characterized by defective microbial clearance and increased production of inflammatory cytokines (Benarafa et al. [@CR11]; Gong et al. [@CR32]). Neutrophil extracellular traps (NETs) are web of nuclear DNA, histones, and antimicrobial molecules released by neutrophils following stimulation by endogenous and pathogen-associated inflammatory mediators. The generation of NETs, or NETosis, was initially described as the ultimate effort by neutrophils to contain microbes and prevent their dissemination by executing this form of programmed cell death (Brinkmann et al. [@CR19]; Fuchs et al. [@CR30]). However, some agonists, such as *Staphylococcus aureus*, may not require neutrophil death for NET release (Pilsczek et al. [@CR59]); and GM-CSF-primed neutrophils release NETs composed of mitochondrial DNA following stimulation with complement C5a (Yousefi et al. [@CR78]). In vitro, *serpinb1a* ^−/−^ neutrophils release more NETs than wild-type neutrophils in response to agonists that induce NETs via reactive oxygen species-dependent and species-independent routes (Farley et al. [@CR29]). These findings suggest that SERPINB1 regulates a conserved portion of the NET release pathway. SERPINB1 was also shown to regulate DNA release from activated neutrophils in vivo following *Pseudomonas* infection. Yet, despite producing more NETs, neutropenic *serpinb1a* ^−/−^ mice fail to control *Pseudomonas* infection in the lung and cannot prevent systemic bacterial spreading (Benarafa et al. [@CR11]; Farley et al. [@CR29]). On the contrary, increased NET generation in these mice may contribute to increased inflammation and tissue injury as observed during influenza infection (Gong et al. [@CR32]).

Several questions thus remain on the potential molecular partners of SERPINB1 in DNA release and associated inflammation. Potential mechanistic pathways include inhibition of NE activity, which is required for NET generation (Papayannopoulos et al. [@CR57]). Moreover, *prtn3* ^−/−^ mice show reduced inflammation and increased survival in a peritonitis model (Loison et al. [@CR49]). Because SERPINB1 translocates to the nucleus during NET generation and is associated with chromatin, it was also hypothesized that SERPINB1 is involved in chromatin decondensation (Popova et al. [@CR60]; Farley et al. [@CR29]).

SERPINB6 and Deafness {#Sec18}
---------------------

A homozygous truncating mutation in *SERPINB6* is associated with non-syndromic sensorineural hearing loss in humans (Sirmaci et al. [@CR70]). Most strikingly, progressive age-related hearing loss is also observed in *serpinb6a* ^−/−^ mice (Tan et al. [@CR72]). Serpinb6a is expressed in cells of the cochlea and its absence leads to degeneration of the organ of Corti, which is composed of hair cells required for transmitting auditory signals. Whether inhibition of proteases, and CG in particular, is involved in this process remains to be determined.
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